Nanotechnology for prostate cancer treatment inches toward reality
CANCER DIGEST – Oct. 19, 2024 – Using nanotechnology to treat prostate cancer, researchers eliminated tumors in 73 percent of men treated.
Olaparib may be sufficient for PSA recurrent prostate cancer among men with BRCA2 alterations
CANCER DIGEST – Aug. 24, 2024 – Men with mutations in a certain gene and whose prostate cancer is recurring as judged by a rising PSA,...
Urine test IDs high-grade vs. low-grade prostate cancer
Test could significantly reduce unnecessary biopsies CANCER DIGEST – April 20, 2024 – University of Michigan researchers have developed a...
Combining MRI with PSA can avoid unnecessary biopsies
CANCER DIGEST – April 1, 2024 – An MRI of the prostate combined with a PSA test can determine clinically significant prostate cancer,...
Confirmation of combination hormone blocking therapy approach for recurrent prostate cancer
CANCER DIGEST – Jan. 28, 2024 – A new multi-center study, led by Rahul Aggarwall, MD, a professor at UCSF School of Medicine, has shown...
Could common diabetes drug slow down aggressive prostate cancer?
CANCER DIGEST – Dec. 16, 2023 – A new study shows that men whose prostate tumors have low levels of a certain gene are both more likely...
